Phase I and Correlative Study of Combination Bryostatin 1 and Vincristine in Relapsed B-Cell Malignancies

Clinical Cancer Research

Volumn 9, Issue 16 I, 2003, Pages 5929-5935

  Dowlati, Afshin ^a,c   Lazarus, Hillard M ^a   Hartman, Paul ^a   Jacobberger, James W ^a   Whitacre, Cecilia ^a   Gerson, Stanton L ^a   Ksenich, Pamela ^a   Cooper, Brenda W ^a   Frisa, Phyllis S ^a   Gottlieb, Megan ^a   Murgo, Anthony J ^b   Remick, Scot C ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRYOSTATIN 1; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISONE; RITUXIMAB; VINCRISTINE;

AGED; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CORRELATION ANALYSIS; DRUG EFFICACY; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; MYALGIA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; FEMALE; FLOW CYTOMETRY; HUMANS; LACTONES; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPHOMA, NON-HODGKIN; MACROLIDES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; SALVAGE THERAPY; VINCRISTINE;

EID: 0347995049     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Pettit, G. R., Herald, S. L., Doubek, D. L., and Herald, D. Isolation and structure of bryostatin 1. J. Am. Chem. Soc., 104: 6846-6848, 1982.
2. Hornung, R. L., Pearson, J. W., Beckwith, M., and Longo, D. L. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res., 52: 101-107, 1992.
3. Jones, R. J., Sharkis, S. J., Miller, C. B., Rowinsky, E. K., Burke, P. J., and May, W. S. Bryostatin 1, a unique biological response modifier: antileukemic activity in vitro. Blood, 75: 1319-1323, 1990.
4. Dale, I. L., and Gescher, A. Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma. Int. J. Cancer, 43: 158-163, 1989.
5. Stanwell, C. A., Gescher, A., Bradshaw, T. D., and Pettit, G. R. The role of protein kinase C isoenzymes in the growth inhibition caused by bryostatin 1 in human A549 and MCF-7 breast carcinoma cells. Int. J. Cancer, 56: 585-592, 1994.
6. 2+ sensitive, phospholipid-dependent kinase activity in phorbol ester-treated 3T3 cells. Biochem. Biophys. Res. Commun., 120: 1053-1059, 1984.
7. Lee, H. W., Smith, L., Pettit, G. R., and Smith, J. B. Bryostatin 1 and phorbol ester down-modulate protein kinase C-∝ and -ε via the ubiquitin/proteasome pathway in human fibroblasts. Mol. Pharmacol., 51: 439-447, 1997.
8. Wall, N. R., Mohammad, R. M., Reddy, K. B., and Al-Katib, A. M. Bryostatin I induces ubiquitination and proteosome degradation of Bcl-2 in the human acute lymphoblastic leukemia cell line. Rehab. Int. J. Mol. Med., 5: 165-171, 2000.
9. Trenn, G., Pettit, G. R., Takayama, H., Hu-Li, J., and Sitkovsky, M. V. Immunomodulating properties of a novel series of protein kinase C activators. The bryostatins. J. Immunol., 140: 433-439, 1988.
10. Mohammad, R. M., Diwakaran, H., Maki, A., Emara, M. A., Pettit, G. R., and Redman, B. Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Leukemia Res., 19: 667-673, 1995.
11. Al-Katib, A. M., Smith, M. R., Kamanda, W. S., Pettit, G. R., Hamdan, M., and Mohamed, A. N. Bryostatin I down-regulates mdr 1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin. Cancer Res., 4: 1305-1314, 1998.
12. Mohammad, R. M., Al-Katib, A., Pettit, G. R., and Sensenbrenner, L. L. Successful treatment of human Waldenstrom's macroglobulinemia with combination biological and chemotherapy agents. Cancer Res., 54: 165-168, 1994.
13. Trotti, A., Byhardt, R., Stetz, J., Gwede, C., Corn, B., Fu, K., Gunderson, L., McCorkmick, B., Morrisintigral, M., Rich, T., Shipley, W., and Curran, W. Common toxicity criteria: version 2.0 an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 47: 13-47, 2000.
14. Cheson, B. D., Bennett, J. M., Rai, K. R., Grever, M. R., Kay, N. E., Schiffer, C. A., Oken, M. M., Keating, M. J., Boldt, D. H., Kempin, S. J., et al. Guidelines for clinical protocols for chronic lympocytic leukemia: Recommendations of the National Cancer Institute-sponsored Working Group. Am. J. Hematol., 29: 152-163, 1988.
15. Blade, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., and Vesole, D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br. J. Haematol., 102: 1115-1124, 1998.
16. Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., and Carbone, P. P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol., 5: 649-655, 1982.
17. 2+-mediated endonuclease activation. Science (Wash. DC), 242: 256-259, 1988.
18. Whitacre, C. M., and Berger, N. A. Factors affecting topotecan-induced programmed cell death: adhesion protects cells from apoptosis and impairs cleavage of poly(ADP-ribose) polymerase. Cancer Res., 57: 2157-2163, 1997.
19. Prendiville, J., Crowther, D., Thatcher, N., Woll, P. J., Fox, B. W., McGown, A., Testa, N., Stern, P., McDermott, R., Potter, M., et al. A Phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br. J. Cancer, 68: 418-424, 1993.
20. Jayson, G. C., Crowther, D., Prendiville, J., McGown, A. T., Scheid, C., Stern, P., Young, R., Brenchley, P., Chang, J., Owens, S., et al. A Phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br. J. Cancer, 72: 461-468, 1995.
21. Varterasian, M. L., Mohammad, R. M., Eilender, D. S., Hulburd, K., Rodriguez, D. H., Pemberton, P. A., Rodriguez, D. H., Spadoni, V., Eilender, D. S., Murgo, A., Wall, N., Dan, M., and Al-Katib, A. M. Phase II study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J. Clin. Oncol., 16: 56-62, 1998.
22. Berkow, R. L., and Kraft, A. S. Bryostatin, a non-phorbol marocyclic lactone, activates intact human polymorphonuclear leukocytes and binds to the phorbol ester receptor. Biochem. Biophys. Res. Commun., 131: 1109-1116, 1985.
23. Sharkis, S. J., Jones, R. J., Bellis, M. L., Demetri, G. D., Griffin, J. D., Civin, C., and May, W. S. The action of bryostatin on normal human hematopoietic progenitors is mediated by accessory cell release of growth factors. Blood, 76: 716-720, 1990.
24. Mohammad, R. M., Wall, N. R., Dutcher, J. A., and Al-Katib, A. M. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Clin. Cancer Res., 12: 4950-4956, 2000.
25. Lilly, M., Vo, K., Le, T., and Takahashi, G. Bryostatin 1 acts synergistically with interleukin-1α to induce secretion of G-CSF and other cytokines from marrow stromal cells. Exp. Hematol., 24: 613-621, 1996.
26. Bosco, M. C, Rottschaffer, S., Taylor, L. S., Ortaldo, J. L., Longo, D. L., and Espinoza-Delgado, I. The antineoplastic agent bryostatin 1 potently activates human monocytes to produce cytokines. Synergy with interleuklin-2. Proc. Am. Soc. Clin. Oncol. 16: 429a, 1997.
27. Philip, P. A., Rea, D., Thavasu, P., Carmichael, J., Stuart, N. S. A., Rockett, H., Talbot, D. C., Ganesan, T., Pettit, G. R., Balkwill, F., et al. Phase I study of Bryostatin 1: assessment of interleukin 6 and tumor necrosis factor induction in vivo. J. Natl. Can. Inst. (Bethesda), 85: 1812-1818, 1993.
28. Grant, S., and Jarvis, W. D. Modulation of drug-induced apoptosis by interruption of the protein kinase C signal transduction pathway: a new therapeutic strategy. Clin. Cancer Res., 2: 1915-1920, 1996.